Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX105 in healthy volunteers
NCT05288881Phase 1Completed
- Sponsor
- Annexon Biosciences
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune diseases and neurodegenerative diseases comparing ANX105 with Placebo (2 arms). Primary endpoint: Number of Participants Who Experienced Treatment-Emergent Adverse Events. Started Feb 2022; status: completed.
02
Drugs
ANX105
03
Conditions
autoimmune diseasesneurodegenerative diseases
Beyond the preview
Go deeper on NCT05288881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288881.